So, here's a nice way to start your Tuesday: wake up to find out your stock is being bought for a huge premium. That's the reality for shareholders of Avanos Medical Inc. (AVNS) this morning. The medical device company announced it's going private in a $1.27 billion all-cash buyout by private equity firm American Industrial Partners (AIP).
If you're not familiar, Avanos makes devices for things like pain management, digestive health, and respiratory care. And today, it's making its investors very happy. The stock was up a staggering 69.03% in premarket trading, according to market data.
The Deal: A Simple, Fat Premium
The terms are straightforward, which is often the best kind of deal. AIP is offering $25.00 in cash for each share of Avanos. Let's put that in perspective. Avanos closed on Monday, April 13, 2026, at $14.53. This offer represents a premium of about 72.1% over that price. That's not a little bump; that's a "we really want this company" premium.
The total enterprise value for the transaction is roughly $1.272 billion. It's an all-cash deal, which means shareholders get a clean exit with no funny business in stock or complicated financing. The Avanos board has already given its unanimous thumbs-up.
Why Now? A Vote of Confidence
These deals don't happen in a vacuum. The announcement talks about AIP's confidence in Avanos's growth potential. The idea is that as a private company, with the operational and financial support of a private equity owner, Avanos can focus on innovation and executing its strategy away from the quarterly earnings spotlight.
The transaction is expected to close in the second half of 2026, assuming it gets the necessary regulatory approvals. So there's still some waiting to do, but the path seems clear.
Coming Off a Strong Quarter
It probably doesn't hurt that Avanos is coming into this deal with some momentum. The company recently reported its fourth-quarter and full-year 2025 results, and it was a beat.
For the quarter, adjusted earnings came in at 29 cents per share, topping the consensus estimate of 25 cents. Sales were $180.9 million, also beating Wall Street's expectation of $174.7 million.
Looking ahead, the company's guidance for fiscal 2026 is for adjusted earnings between 90 cents and $1.10 per share, with sales in the range of $700 million to $720 million. That sales outlook brackets the consensus estimate of $710 million nicely.
So, you have a company that just beat expectations, offered solid guidance, and is now getting bought for a 72% premium. It's a pretty good sequence of events if you're a shareholder. The market's reaction—that nearly 70% premarket jump to $24.56—suggests everyone agrees the price is right.
For Avanos, it's the end of its run as a public company. For its shareholders, it's a very profitable Tuesday.
.jpeg)
